FibroGen's Pamrevlumab Faces Setbacks in Phase 3 Trials for Lung Fibrosis Treatment
TL;DR
FibroGen's Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change from baseline in forced vital capacity (FVC) at week 48. The study compared treatment with pamrevlumab to placebo. Pamrevlumab was generally safe and well tolerated. FibroGen plans to implement a significant cost reduction effort in the U.S. with the intent to extend its cash runway into 2026.
Topics:businesshealthcare#clinical-trials#fibrogen#healthcare#idiopathic-pulmonary-fibrosis#pamrevlumab#phase-3-study
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis Yahoo Finance
- Analyst Downgrades FibroGen On Questions Regarding Future Direction - FibroGen (NASDAQ:FGEN) Benzinga
- Second Strike for FibroGen’s Pamrevlumab—First Duchenne, Now Lung Fibrosis BioSpace
- FGEN Stock Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug Investor's Business Daily
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints TipRanks
Want the full story? Read the original reporting
Read on Yahoo Finance